Jocil (JOCIL)

Score breakdown: P/E: 2/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Let me start with what I like. Jocil sells at ₹126.40 while its book value is ₹236.09—a price-to-book of 0.54. The balance sheet is conservatively run, with debt-to-equity of 0.03 and promoters owning 55%. That is the kind of margin-of-safety starting point Graham would notice. But a cheap price cannot turn a poor business into a wonderful one. Jocil is a commodity chemical company. It has no pricing power; the market decides the price. ROCE is only 0.71%, meaning the capital employed is not earning anywhere near a satisfactory return. The latest quarter shows sales of ₹263 crore but net profit of just ₹2 crore. That is less than a 1% net margin. The 160% profit growth sounds impressive, but it is off a very low base, and the 19.37 P/E on those small earnings is not a bargain. The PEG of 0.22 is a statistic, not a philosophy. Sales grew 19.45%, and the Piotroski score of 7 suggests improving financial health, so there may be a cyclical or operational recovery underway. But I would be buying this for the assets, not for the earning power. In an asset play, I must be sure liquidation or earning power will close the gap between ₹126 and ₹236 of book value. Until I see sustained returns on capital, better margins, and a clear catalyst, I remain cautious. This is not the kind of predictable compounder Buffett loves; it is a potential bargain-bin special that demands constant attention.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer